Syntis Bio wants to put a detour in your daily pill

The useful thing about a mussel is that it stays put. Water moves; the animal holds on. For researchers trying to deliver medicine through the small intestine, that modest achievement suggested an answer to a troublesome question: how do you make something linger in a place designed to keep things moving?

Syntis Bio has built a company around the answer. Its experimental platform, SYNT, forms a temporary coating on intestinal tissue. One version aims to change where food is absorbed; others could keep therapeutic enzymes working locally or improve drug absorption. The lead test of the idea is obesity, a crowded market in which changing the route may matter as much as changing the molecule.

• The idea: a daily tablet that temporarily redirects nutrients further along the small intestine.
• The evidence: early human tolerability and hormone findings, with a short-term weight-loss signal.
• The next hurdle: longer trials that establish whether the benefit lasts.

The problem was swallowing

The origin was less fashionable than weight loss. Researchers in Robert Langer’s and Giovanni Traverso’s MIT laboratories were working on oral medicines for children, supported by the Gates Foundation. A capsule is convenient only for someone who can swallow it. A liquid offers another route, provided the medicine can do its work before the digestive tract carries it away.

“Children often aren’t able to take solid dosage forms like capsules and tablets.”

Giovanni Traverso · MIT News, 2020

In 2020, MIT described a synthetic lining tested in pigs. Researchers explored enzyme delivery, sustained drug release and restrictions on glucose absorption. Those were strikingly different jobs for one coating. The company formed in 2022 and launched publicly in June 2024. What began as a delivery problem had opened a second question: could changing an intestinal surface change metabolism?

A detour, renewed daily

SYNT stands for SYNthetic Tissue-lining. Its mussel-inspired polymer chemistry produces a polydopamine coating on tissues rich in catalase, an enzyme concentrated in the upper small intestine. The proposed advantage is time at the right address: a lining that remains for up to 24 hours, then clears naturally.

SYNT-101, the lead obesity candidate, uses that surface as a barrier. It is designed to temporarily restrict nutrient absorption in the duodenum and send nutrients further down the intestine. There, food can stimulate the body’s own satiety signals. Syntis is trying to reproduce an aspect of gastric bypass’s metabolic response through a daily tablet.

The distinction matters. SYNT-101 is not a GLP-1 receptor agonist. It seeks a local intestinal action that changes several endogenous hormone signals, including GLP-1 and PYY. Nor does a temporary coating reproduce every consequence of surgery. Its value will depend on how much useful metabolic change the detour produces, and for how long.

Twenty-eight days is a beginning

In April 2025, Syntis reported a nine-person pilot examining safety, tissue findings and nutrient diversion. The formal SYNTIETY-1 Phase 1/1b study followed. By July 2026, the company had single-dose results in 32 healthy adults: evidence of delayed glucose absorption and changes in satiety hormones. Mild, self-limited hypoglycemia during glucose testing was the only treatment-related adverse event reported.

September brought the 28-day, multiple-dose results in 23 adults with overweight or obesity. This portion was randomized, double-blind and placebo-controlled. Syntis reported greater weight loss than placebo across all three dose cohorts, no discontinuations or dose reductions, and gastrointestinal adverse events at a similar rate to placebo.

Exploratory measurements also showed increases in GLP-1 and PYY and a decrease in ghrelin. These are early findings reported by the company. Four weeks cannot establish durable weight management or chronic safety, and the announcement supplied no numerical weight-loss percentage. A reader should resist mentally upgrading a plausible mechanism into a proven treatment.

The bill before the pill

Syntis’s disclosed equity financing totals $48.5 million: a $15.5 million seed round in 2023 and a $33 million Series A announced in July 2025. Cerberus Ventures led the latter, joined by investors including Mansueto Investments, Woori Venture Partners and existing backers. Syntis separately announced up to $5 million in NIH awards.

That is capital raised, not the cost of producing an approved medicine. The business currently rests on developing proprietary therapies and pursuing pharmaceutical collaborations. Patients are intended beneficiaries; trial participants are the people using the experimental product today. There is no approved SYNT-101 pill to buy.

The founding team combines Langer’s biomaterials work, Traverso’s gastroenterology and engineering, and CEO Rahul Dhanda’s company-building experience. Dhanda previously co-founded Sherlock Biosciences. In his account, a cold email sent to Langer near the end of his MIT MBA began the relationship that eventually connected these founders.

Rahul DhandaCompany building

Robert LangerBiomaterials

Giovanni TraversoGI medicine & engineering

The leadership additions point toward the next stage of that work. Chief Development Officer David Rosenbaum previously helped guide two Ardelyx medicines through FDA approval. Syntis appointed him in March 2026 and added CFO Matt Dallas in June. Turning a platform into a medicine requires people who have managed the less photogenic parts of development.

The same surface, different patients

The obesity program competes for relevance alongside established medicines and bariatric surgery. Syntis also sees possible combination use with other weight-loss therapies. Better tolerability, affordability and complementary efficacy are ambitions to test, rather than advantages already settled.

Beyond obesity, Syntis acquired engineered enzymes from Codexis in April 2024. Its current pipeline names SYNT-212 for homocystinuria and SYNT-213 for maple syrup urine disease. Both combine enzymes with the platform to prolong gut-restricted activity. Preclinical obesity programs SYNT-113 and SYNT-115 pair the lining with a small molecule and a biologic, respectively.

For a pharmaceutical partner, the appeal extends beyond obesity. A therapeutic that works locally might benefit from longer intestinal residence; another might need help crossing into circulation. Syntis describes both applications. Each pairing still requires its own evidence. Success with a nutrient barrier would not automatically validate a different drug carried by the same platform.

The lesson a reader can borrow is a development strategy: examine where a therapy works and how long it stays there. Syntis’s expansion follows that delivery question across diseases. But the strategy depends on repeatable tissue targeting, useful clinical effects and acceptable long-term consequences. An elegant coating earns attention; a medicine must earn its place in someone’s daily life.